US equities |
SPCX $167.01 ▲+5.06% NVDA $236.87 ▲+1.25% MU $1,063.25 ▼-1.08% TSLA $377.35 ▲+1.82% MSFT $526.50 ▲+1.73% SNDK $1,709.28 ▼-0.62% INTC $117.37 ▼-1.64% META $744.68 ▲+2.28%
FinancialContent

Articles published by Erasca, Inc.

News headline image
Erasca Reports First Quarter 2024 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces $45 Million Oversubscribed Private Placement Financing
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS NVS
News headline image
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca to Present at Upcoming Investor Conferences in November
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca to Present at the Cantor Global Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Reports Second Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Reports First Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS NVS
News headline image
Erasca Announces Pricing of Underwritten Offering of Common Stock
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca to Present at Upcoming Investor Conferences
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Reports Third Quarter 2022 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS
News headline image
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
From Erasca, Inc.
Via GlobeNewswire
Tickers ERAS PFE